Jagsonpal Pharmaceuticals Ltd Forensic Report - SOIC x StockScans Report

as of Aug 2026

Jagsonpal Pharmaceuticals has received seven consecutive clean statutory audit opinions, and its internal financial controls have been unmodified every year from FY2020 through FY2026. That clean record sits alongside a cluster of unresolved items: two confirmed tax and customs demands totalling roughly ₹10 crore are dismissed as immaterial, the Yash Pharma acquisition recognised ₹82.3 crore of intangibles and ₹9.69 crore of goodwill with no impairment despite a rising discount rate, and the company's own filings show obligations that sit outside its "debt-free" claim.

Key findings

  1. Two confirmed tax and customs demands are dismissed as immaterial Major - A Customs Authority order dated 25 February 2025 confirmed differential duty of ₹5,09,79,206 with an equivalent penalty and interest, and an Income Tax Department order dated 12 March 2026 raised a demand of ₹4,81,61,360. The FY2025-26 notes state the company believes none of its contingent liabilities are material individually or in aggregate, without quantifying the exposure. The two demands together equal roughly 22% of annual PAT.
  2. Yash Pharma acquisition recognised ₹82.3 crore of intangibles with no impairment despite a rising discount rate Major - Jagsonpal acquired the dermatology and childcare divisions of Yash Pharma, recognising ₹82.3 crore of identifiable intangibles and ₹9.69 crore of goodwill. The discount rate used for impairment testing rose from 20.60% as at 31 March 2025 to 23.50% as at 31 March 2026, yet no impairment was recognised and sensitivity analysis concluded no reasonable change would cause recoverable amount to fall below carrying value. A second acquisition, 85% of Aequitas Healthcare for ₹20.8 crore, was disclosed with no goodwill or intangible details.
  3. Reported profits have been shaped by policy changes, restatements, and offsetting exceptional items Major - In FY2020-21, a deferred tax accounting policy change reduced tax expenditure by 1.19 crore and increased profit by the same amount. A FY2022-23 restatement reduced FY2021-22 total comprehensive income from 20.95 crore to 19.9 crore, and a further restatement on 23 May 2023 reduced income-tax assets by 8.36 crore. The FY2024-25 sale of the Faridabad factory booked a profit of ₹23.36 crore with a current tax impact of ₹4.97 crore and reversal of deferred tax liabilities of ₹2.27 crore.
  4. The Aequitas acquisition leaves 15% with the target's promoters and no disclosed terms Major - Jagsonpal had no subsidiary, joint venture or associate as at 31 March 2026, then consummated the 85% acquisition of Aequitas Healthcare on 17 July 2026. The remaining 15% stays with Aequitas' existing promoters, and management did not disclose any put/call options, earn-out terms, or contingent consideration relating to that retained stake. Management framed the deal at "an enterprise value of about Rs.25 crores" while paying ₹20.8 crore for 85%, a gap left unexplained.
  5. Revenue recognition carries recurring auditor scrutiny and an unexplained growth variance Major - The auditor flagged revenue from sale of products as a Key Audit Matter in both FY2024-25 and FY2022-23, citing risk of overstatement and judgment on timing of control transfer. Management acknowledged in Q1 FY2027 an unexplained variance between reported revenue growth of 9% and external market data showing 18.9%, stating "we are looking into it as to why this has happened" without a resolution timeline. A single external customer contributed 19% of FY2025-26 revenue.
  6. Board and KMP turnover has been continuous since the 2022 control change Major - Five directors resigned effective 29 June 2022 and the Chairman & MD resigned 16 July 2022, coinciding with the Infinity Holdings acquisition of 43.73% of voting capital. Four CFOs have come and gone since February 2022, and three Company Secretaries since December 2022. Managing Director Manish Gupta holds 2.72% of shares, making him the largest non-promoter shareholder, and his remuneration was increased to ₹1,50,00,000 per annum effective 16 July 2025.
  7. The "debt-free" claim sits alongside deferred payment and lease obligations Major - The FY2025-26 Corporate Governance report states no borrowing and no outstanding credit rating, and a postal ballot notice dated 25 March 2026 states "The Company is a debt free entity". The FY2024-25 MD&A attributes an increase in non-current liabilities to a "deferred payment obligation against brands acquired" alongside a Mumbai office lease. Operating lease commitments stood at INR 242.72 lacs as at 31 March 2022.
  8. Seven clean opinions with recurring audit-trail and IEPF exceptions that never rise to qualification Major - Walker Chandiok & Co LLP issued an unqualified opinion for FY2025-26 with no Emphasis of Matter paragraphs. The audit-trail feature was not enabled at database level for part of FY2024, enabled only for certain key users in FY2025, and fully enabled only from 01 January 2026. The Secretarial Audit Report for FY2026 was qualified for delay in transferring unclaimed dividends to IEPF, a remark that also appeared in FY2025.

What to watch

Bottom line: This is a record with clean audit opinions and unmodified internal control statements every year, but the substance beneath those opinions carries recurring exceptions. The risk character is one of disclosed-but-unresolved items: confirmed tax demands dismissed as immaterial, an acquisition with rising discount rates and no impairment, and compliance exceptions that persist across years without becoming qualifications. Watch whether the appeals resolve, whether the Aequitas deal gets proper accounting disclosure, and whether the audit-trail and IEPF exceptions finally clear in the FY2026-27 report.